Proficio Capital Partners LLC Makes New Investment in Anavex Life Sciences Corp. (NASDAQ:AVXL)

Proficio Capital Partners LLC purchased a new stake in shares of Anavex Life Sciences Corp. (NASDAQ:AVXL) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 19,558 shares of the biotechnology company’s stock, valued at approximately $210,000.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. Berkshire Money Management Inc. bought a new position in Anavex Life Sciences during the 4th quarter worth about $107,000. Fiduciary Alliance LLC purchased a new stake in shares of Anavex Life Sciences in the 4th quarter worth approximately $119,000. D.A. Davidson & CO. bought a new position in shares of Anavex Life Sciences during the fourth quarter valued at approximately $122,000. Orion Capital Management LLC increased its holdings in Anavex Life Sciences by 666.7% during the third quarter. Orion Capital Management LLC now owns 11,500 shares of the biotechnology company’s stock valued at $65,000 after buying an additional 10,000 shares during the period. Finally, PVG Asset Management Corp bought a new position in Anavex Life Sciences in the third quarter worth approximately $74,000. 31.55% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

AVXL has been the topic of a number of analyst reports. HC Wainwright reiterated a “buy” rating and issued a $42.00 price target on shares of Anavex Life Sciences in a report on Tuesday, February 18th. D. Boral Capital reiterated a “buy” rating and issued a $46.00 target price on shares of Anavex Life Sciences in a report on Wednesday, February 12th.

Anavex Life Sciences Stock Up 1.9 %

Shares of AVXL opened at $9.54 on Friday. The company has a 50 day moving average of $9.02 and a two-hundred day moving average of $8.25. Anavex Life Sciences Corp. has a twelve month low of $3.25 and a twelve month high of $14.44. The company has a market cap of $811.51 million, a price-to-earnings ratio of -17.35 and a beta of 0.94.

Anavex Life Sciences (NASDAQ:AVXL) last posted its quarterly earnings data on Wednesday, February 12th. The biotechnology company reported ($0.14) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.03. On average, sell-side analysts expect that Anavex Life Sciences Corp. will post -0.69 EPS for the current year.

Anavex Life Sciences Profile

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome.